ephroprotection in severe Rhabdomyolysis by use of a HemAdsorber
Phase 4
- Conditions
- Rhabdomyolysis
- Registration Number
- DRKS00021049
- Lead Sponsor
- niversitätsklinikum des Saarlandes Klinik für Anästhesiologie, Intensivmedizin und Schmerztherapie Geb. 57
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
severe rhabdomyolysis
- indication for continuous renal replacement therapy in the IC
Exclusion Criteria
- pregnancy
- simultaneous participation in another study
- previous participation in the same study
- no informed consent obtainable
- patients permanently not able to give informed consent (e.g. dementia, permanent legal representative)
- contraindication to or refusal to accept hemodialysis treatment
- impossibility or contraindication to implantation of a dialysis catheter
- Impossibility to achieve high blood flow (200 ml/hour) through the dialysis catheter
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method percent fall in myoglobin serum concentration during the first 24 hours of therapy
- Secondary Outcome Measures
Name Time Method Myoglobin elimination rates will be determined by measuring myoglobin concentrations in patient blood (pre-CS), after passage through the hemadsorber (post-CS) and after passage through the hemofilter (post-Filter), as well as in patient urine and in the effluate from the hemodialysis device.<br>It will also be examined whether the hemabsorber shows saturation kinetics for myoglobin over 24 hours.<br>In addition, mortality and necessity of renal replacement therapy over 30 days after initiation of therapy will be monitored.